Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

Haematologica, Vol 92, Issue 3, 429-430 doi:10.3324/haematol.10632
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Iacobucci, I.
Right arrow Articles by Martinelli, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Iacobucci, I.
Right arrow Articles by Martinelli, G.

Chronic Myeloid Leukemia

Monitoring BCR-ABL transcript levels by real-time quantitative polymerase chain reaction: a linear regression equation to convert from BCR-ABL/B2M ratio to estimated BCR-ABL/ABL ratio

Ilaria Iacobucci, Livia Galletti, Marilina Amabile, Simona Soverini, Michele Baccarani, Giovanni Martinelli

From Department of Hematology/Oncology "L. and A. Seràgnoli" S. Orsola Malpighi Hospital, University of Bologna, Bologna, Italy

Correspondence: Giovanni Martinelli, Molecular Biology Unit, Department of Hematology/Oncology "L. and A. Seràgnoli" S. Orsola Malpighi Hospital, University of Bologna, Via Massarenti, 9, 40138 Bologna, Italy. Phone: international +0039.051.6363829. Fax: international + 0039.051.6364037. E-mail: gmartino{at}kaiser.alma.unibo.it

In order to overcome the problem of different control genes for BCR-ABL normalization, we used a linear regression equation to compare our results previously obtained using B2M as the control gene with those calculated using the ABL gene and validated the slope as a factor to convert from B2M to ABL results.

Key words: BCR-ABL ratio, RT-PCR.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
F. Palandri, I. Iacobucci, S. Soverini, F. Castagnetti, A. Poerio, N. Testoni, G. Alimena, M. Breccia, G. Rege-Cambrin, M. Tiribelli, et al.
Treatment of Philadelphia-Positive Chronic Myeloid Leukemia with Imatinib: Importance of a Stable Molecular Response
Clin. Cancer Res., February 1, 2009; 15(3): 1059 - 1063.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
F. Palandri, I. Iacobucci, F. Castagnetti, N. Testoni, A. Poerio, M. Amabile, M. Breccia, T. Intermesoli, F. Iuliano, G. Rege-Cambrin, et al.
Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-{alpha}: 5-year outcome
Haematologica, May 1, 2008; 93(5): 770 - 774.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Palandri, I. Iacobucci, G. Martinelli, M. Amabile, A. Poerio, N. Testoni, S. Soverini, F. Castagnetti, A. De Vivo, M. Breccia, et al.
Long-Term Outcome of Complete Cytogenetic Responders After Imatinib 400 mg in Late Chronic Phase, Philadelphia-Positive Chronic Myeloid Leukemia: The GIMEMA Working Party on CML
J. Clin. Oncol., January 1, 2008; 26(1): 106 - 111.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
F. Palandri, I. Iacobucci, F. Quarantelli, F. Castagnetti, D. Cilloni, M. Baccarani, and on behalf of the GIMEMA Working Party on CML
Long-term molecular responses to imatinib in patients with chronic myeloid leukemia: comparison between complete cytogenetic responders treated in early and in late chronic phase
Haematologica, November 1, 2007; 92(11): 1579 - 1580.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2007 by the Ferrata Storti Foundation.